Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Patents Analysis
7. Spain Liquid Biopsy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
7.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
7.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
7.2.4. By Sample (Blood, Urine, Saliva, Others)
7.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
7.2.6. By Application (Oncological v/s non-Oncological)
7.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
7.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
7.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
7.2.8. By Region (Central Region North Spain; Aragon & Catalonia; Andalusia, Murcia & Valencia; Madrid, Extremadura & Castilla)
7.2.9. By Company (2022)
7.3. Market Map
7.3.1. By Offering
7.3.2. By Technology
7.3.3. By Workflow
7.3.4. By Sample
7.3.5. By Circulating Biomarker
7.3.6. By Application
7.3.7. By End User
7.3.8. By Region
8. Central Region North Spain Liquid Biopsy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
8.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
8.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
8.2.4. By Sample (Blood, Urine, Saliva, Others)
8.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
8.2.6. By Application (Oncological v/s non-Oncological)
8.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
9. Aragon & Catalonia Liquid Biopsy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
9.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
9.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
9.2.4. By Sample (Blood, Urine, Saliva, Others)
9.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
9.2.6. By Application (Oncological v/s non-Oncological)
9.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
10. Andalusia, Murcia & Valencia Liquid Biopsy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
10.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
10.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
10.2.4. By Sample (Blood, Urine, Saliva, Others)
10.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
10.2.6. By Application (Oncological v/s non-Oncological)
10.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
11. Madrid, Extremadura & Castilla Liquid Biopsy Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
11.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
11.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
11.2.4. By Sample (Blood, Urine, Saliva, Others)
11.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
11.2.6. By Application (Oncological v/s non-Oncological)
11.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Development
13.2. Mergers & Acquisitions
13.3. Product Launches
14. Policy & Regulatory Landscape
15. Porter’s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. Spain Economic Profile
17. Competitive Landscape
17.1. Business Overview
17.2. Product Offerings
17.3. Recent Developments
17.4. Financials (As Reported)
17.5. Key Personnel
17.6. SWOT Analysis
17.6.1. Thermo Fisher Scientific SL
17.6.2. Sysmex Espana S.L.
17.6.3. OncoDNA SA
17.6.4. Atrys Health SA
17.6.5. Biocartis Group NV
18. Strategic Recommendations